Mayne Pharma Group (MYX) Price & Analysis

Compare

52 Followers

MYX Stock Chart & Stats

AU$6.01

-AU$0.13(-2.74%)

At close: Jan 09 4:00 PM EST

AU$6.01

-AU$0.13(-2.74%)

Day’s Range― - ―

52-Week RangeAU$2.60 - AU$7.31

Previous CloseN/A

Volume149.18K

Average Volume (3M)593.75K

Market Cap

AU$214.49M

Enterprise ValueAU$196.73M

Total Cash (Recent Filing)AU$100.40M

Total Debt (Recent Filing)AU$41.27M

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding81,245,830

10 Day Avg. Volume776,050

30 Day Avg. Volume593,750

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)1.11

Price to Sales (P/S)1.01

P/FCF Ratio79.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$6.10

Price Target Upside1.50% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Stable Capital StructureA debt-to-equity ratio of 0.11 indicates low financial leverage, giving the company structural flexibility to fund operations, absorb revenue shocks, and invest in R&D or manufacturing without heavy interest burdens. This reduces refinancing risk over the medium term.

High Gross MarginA 60%+ gross margin reflects strong unit economics from manufacturing and a favorable product mix (branded/specialty and CDMO). If operating expenses are controlled and sales stabilize, this margin provides durable upside to restore operating profitability and sustain competitive pricing power.

Diversified Pharmaceutical Business ModelMultiple revenue streams—branded commercial products, generics and contract development/manufacturing—create structural resilience. Exposure to U.S. and Australian markets plus CDMO contracts offers repeatable fee income and pathways to scale higher-margin branded sales over time.

Bears Say

Declining Revenue And Persistent LossesSustained revenue decline and ongoing net losses erode scale and margin leverage, worsening unit economics and limiting ability to invest in product launches or commercial expansion. Over months, continued top-line contraction can force cost cuts that impair growth prospects.

Weak Cash Generation And ConversionSeverely negative FCF growth and very low cash conversion indicate the business struggles to turn earnings into cash. This creates durable liquidity pressure, constrains capex and working capital, and increases dependence on external financing for sustaining operations and CDMO commitments.

Negative Return On EquityA deeply negative ROE demonstrates the company is destroying shareholder capital rather than generating returns. Persistently negative ROE undermines investor confidence, makes equity raises dilutive and limits long-term funding options for commercial expansion or product development.

Mayne Pharma Group News

Mayne Pharma Plans New Performance Rights Issue

The latest update is out from Mayne Pharma Group ( ($AU:MYX) ). Mayne Pharma Group has announced a...

5h ago

Mayne Pharma Discloses Equity Holdings as Director Shawn O’Brien Departs Board

Mayne Pharma Group ( ($AU:MYX) ) has shared an announcement. Mayne Pharma Group has announced that director Shawn...

5h ago

Mayne Pharma Frames 1H FY26 Results Around EBITDA and Disclosure Transparency

An update from Mayne Pharma Group ( ($AU:MYX) ) is now available. Mayne Pharma Group has released its...

14h ago

Mayne Pharma lifts margins as dermatology outperforms despite softer cash flow

Mayne Pharma Group ( ($AU:MYX) ) has issued an announcement. Mayne Pharma reported first-half FY26 revenue of A$212.1...

14h ago

Vanguard Group Cuts Stake Below Substantial Holder Threshold in Mayne Pharma

Mayne Pharma Group ( ($AU:MYX) ) just unveiled an announcement. Vanguard Group, through The Vanguard Group, Inc. and...

18d ago

Mayne Pharma Secures Shareholder Backing for Board, Pay and CEO Incentives at AGM

Mayne Pharma Group ( ($AU:MYX) ) has shared an update. Mayne Pharma Group Limited reported that all resolutions...

25d ago

Mayne Pharma Opens Delayed 2025 AGM After Cosette Scheme Setback

The latest announcement is out from Mayne Pharma Group ( ($AU:MYX) ). Mayne Pharma has convened its 2025...

25d ago

Goldman Sachs Ceases to Be Substantial Shareholder in Mayne Pharma

Mayne Pharma Group ( ($AU:MYX) ) has provided an announcement. Goldman Sachs Group, including its Australian subsidiaries, has...

1M ago

Mayne Pharma to Vigorously Contest Cosette Appeal Over FY25 Metrics

Mayne Pharma Group ( ($AU:MYX) ) has provided an update. Mayne Pharma Group has received a formal notice...

1M ago

Mayne Pharma Director Frank Condella Steps Down from Board

Mayne Pharma Group ( ($AU:MYX) ) has provided an update. Mayne Pharma Group has announced that director Frank...

1M ago

Sol-Gel, Mayne Pharma enter product purchase agreement

Sol-Gel Technologies (SLGL) entered into a product purchase agreement with a subsidiary of Mayne Pharma Group (MAYNF) for...

10M ago

SLGL

Mayne Pharma upgraded to Buy from Hold at Canaccord

Canaccord upgraded Mayne Pharma to Buy from Hold with a price target of A$6.69, up from A$3.80, after...

2y ago

Mayne Pharma downgraded to Hold from Buy at Canaccord

Canaccord analyst Elyse Shapiro downgraded Mayne Pharma to Hold from Buy with a price target of A$3.80, down...

3y ago

Dr. Reddy’s to acquire Mayne Pharma for upfront payment of $90M

Dr. Reddy’s Laboratories (RDY) announced that it has entered into a definitive agreement to acquire the U.S. generic...

3y ago

RDY

MYX FAQ

What was Mayne Pharma Group’s price range in the past 12 months?

Mayne Pharma Group lowest share price was AU$2.60 and its highest was AU$7.31 in the past 12 months.

What is Mayne Pharma Group’s market cap?

Mayne Pharma Group’s market cap is AU$214.49M.

When is Mayne Pharma Group’s upcoming earnings report date?

Mayne Pharma Group’s upcoming earnings report date is Aug 20, 2026 which is in 178 days.

How were Mayne Pharma Group’s earnings last quarter?

Currently, no data Available

Is Mayne Pharma Group overvalued?

According to Wall Street analysts Mayne Pharma Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mayne Pharma Group pay dividends?

Mayne Pharma Group pays a Notavailable dividend of AU$0.544 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group dividends here

What is Mayne Pharma Group’s EPS estimate?

Mayne Pharma Group’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mayne Pharma Group have?

Mayne Pharma Group has 81,245,830 shares outstanding.

What happened to Mayne Pharma Group’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Mayne Pharma Group?

Currently, no hedge funds are holding shares in AU:MYX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Mayne Pharma Group Stock Smart Score

Underperform

Fundamentals

Return on Equity

-21.13%

Trailing 12-Months

Asset Growth

-12.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mayne Pharma Group

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Mayne Pharma Group (MYX) Earnings & Revenues

Historic Earnings Reports

MYX Company Deck

MYX Earnings Call

Q2 2026

0:00 / 0:00

MYX Stock 12 Month Forecast

Average Price Target

AU$6.10

▲(1.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"AU$1","8":"AU$8","2.75":"AU$2.75","4.5":"AU$4.5","6.25":"AU$6.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$6.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$6.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$6.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.75,4.5,6.25,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.9523076923076923,3.2146153846153847,3.476923076923077,3.739230769230769,4.001538461538462,4.263846153846154,4.526153846153846,4.788461538461538,5.05076923076923,5.313076923076923,5.575384615384616,5.837692307692308,{"y":6.1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.9523076923076923,3.2146153846153847,3.476923076923077,3.739230769230769,4.001538461538462,4.263846153846154,4.526153846153846,4.788461538461538,5.05076923076923,5.313076923076923,5.575384615384616,5.837692307692308,{"y":6.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.9523076923076923,3.2146153846153847,3.476923076923077,3.739230769230769,4.001538461538462,4.263846153846154,4.526153846153846,4.788461538461538,5.05076923076923,5.313076923076923,5.575384615384616,5.837692307692308,{"y":6.1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 24</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >